CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions
At the Clinical Trials on Alzheimer’s Disease Conference, BMS finally revealed early data for its Alzheimer’s disease psychosis trials of KarXT, marketed as Cobenfy in schizophrenia.
comments(0)
5-min edit window · permanent after that